2019 IPO
TP Therapeutics Stock
TP Therapeutics is a structure-based drug design pharmaceutical company
Sign up today and learn more about TP Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About TP Therapeutics Stock
TP Therapeutics, Inc. is a structure-based drug design pharmaceutical company founded by Dr. J. Jean Cui, the lead inventor of Pfizer's Xalkori(TM) (generic name: crizotinib), the precision oncology drug for non-small cell lung cancer (NSCLC). Xalkori(TM) was approved by US Food and Drug Administration on August 26th, 2011.
Funding History
January 2014 | $1.4M |
---|---|
March 2016 | $18.0M |
May 2017 | $45.0M |
October 2018 | $80.0M |
Management
Founder & CSO
J. Jean Cui
Senior Vice President, Clinical Operations and Regulatory Affairs
John K.C. Lim
CEO
Athena Countouriotis
Co-founder, Chairman, President, and CEO
Y. Peter Li
Vice President of Pre-Clinical Development
Jeffrey P. Whitten